PMID- 27116538 OWN - NLM STAT- MEDLINE DCOM- 20171018 LR - 20180424 IS - 1460-2202 (Electronic) IS - 0271-3683 (Linking) VI - 41 IP - 11 DP - 2016 Nov TI - The Effect of Everolimus on Scar Formation in Glaucoma Filtering Surgery in a Rabbit Model. PG - 1438-1446 AB - PURPOSE: To investigate the efficiency of everolimus on the prevention of postoperative scar in a rabbit model of glaucoma filtering surgery in comparison with mitomycin-C (MMC). MATERIALS AND METHODS: Thirty New Zealand albino rabbits were randomly assigned into 3 groups, each including ten rabbits: an everolimus group (Group 1), a MMC group (Group 2), and a sham group (Group 3). A limbal-based trabeculectomy was performed on the right eyes of all the rabbits. For 28 days following surgery, the eyes were evaluated in terms of intraocular pressure (IOP), morphological and biomicroscopic changes, and complications in the bleb. On the 28th day, four eyes randomized from each group were enucleated and histologically and immunohistochemically analyzed. Transforming growth factor-beta1 (TGF-beta1), metalloproteinase (MMP-2, MMP-9), and proliferative cell nuclear antigen (PCNA) expressions in each group were evaluated. The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method was used for apoptosis. RESULTS: Bleb survival was statistically significantly longer for a period in Group 1 compared to Group 2. When postoperative IOPs of three groups were measured, it was seen that there is significant IOP reduction in all three groups. However, there were increases in the mean IOP values beginning from the 5th day in Group 2 and from the 3rd day in Group 3 while in Group 1 mean IOP values began to increase beginning from 10th day and the mean IOP values in Group 1 remained at a lower level in comparison to the other groups for 28 days (p < 0.05). The expressions of TGF-beta1, MMP-2, MMP-9, and PCNA were reduced in Group 1 compared to other groups. TUNEL positive apoptotic cells were significantly increased in Group 1 compared to other groups (p < 0.05). CONCLUSION: Everolimus appears to suppress the proliferation of fibroblast and thus may provide an effective treatment strategy in glaucoma filtering surgery. FAU - Cinik, Ruken AU - Cinik R AD - a Department of Ophthalmology , Diyarbakir Bismil State Hospital , Diyarbakir , Turkey. FAU - Yuksel, Nursen AU - Yuksel N AD - b Department of Ophthalmology , Kocaeli University, Faculty of Medicine , Kocaeli , Turkey. FAU - Pirhan, Dilara AU - Pirhan D AD - b Department of Ophthalmology , Kocaeli University, Faculty of Medicine , Kocaeli , Turkey. FAU - Aslan, Mehmet Sehmuz AU - Aslan MS AD - c Department of Ophthalmology , Arnavutkoy State Hospital , Istanbul , Turkey. FAU - Subasi, Cansu AU - Subasi C AD - d Center for Regenerative Medicine and Stem Cell Research & Manufacturing (LivMedCell), Liv Hospital , Istanbul , Turkey. FAU - Karaoz, Erdal AU - Karaoz E AD - d Center for Regenerative Medicine and Stem Cell Research & Manufacturing (LivMedCell), Liv Hospital , Istanbul , Turkey. LA - eng PT - Journal Article DEP - 20160426 PL - England TA - Curr Eye Res JT - Current eye research JID - 8104312 RN - 0 (Immunosuppressive Agents) RN - 9HW64Q8G6G (Everolimus) SB - IM MH - Animals MH - Cells, Cultured MH - Cicatrix/etiology/pathology/*prevention & control MH - Disease Models, Animal MH - Everolimus/*pharmacology MH - Fibroblasts/drug effects MH - Filtering Surgery/*adverse effects MH - Glaucoma/physiopathology/*surgery MH - Humans MH - Immunosuppressive Agents/pharmacology MH - Intraocular Pressure MH - Rabbits MH - Treatment Outcome MH - Wound Healing/*drug effects OTO - NOTNLM OT - Everolimus OT - glaucoma OT - mitomycin-C OT - trabeculectomy OT - wound-site healing EDAT- 2016/04/27 06:00 MHDA- 2017/10/19 06:00 CRDT- 2016/04/27 06:00 PHST- 2016/04/27 06:00 [pubmed] PHST- 2017/10/19 06:00 [medline] PHST- 2016/04/27 06:00 [entrez] AID - 10.3109/02713683.2015.1125506 [doi] PST - ppublish SO - Curr Eye Res. 2016 Nov;41(11):1438-1446. doi: 10.3109/02713683.2015.1125506. Epub 2016 Apr 26.